All In MedTech

FDA Clearance Tracker · P980018

DAKO HERCEPTEST

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Sep 25, 1998 (this decision)Source: openFDAMethods & limitations

PMAFirst of its product code

Decided

Sep 25, 1998

Approved

Time to decision

130 days

Received May 18, 1998. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P980018
Device name
DAKO HERCEPTEST
Applicant location
Singapore
Received
May 18, 1998
Decided
Sep 25, 1998
Decision
Approved
Supplements
27 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code MVC

FDA's approval statement

As written in FDA's record.

Approval for the DAKO Herceptest. This device is a semi-quantitative immunohistochemical assay to determine HER2 overexpression in breast cancer tissues routinely processed for histological evaluation. HercepTest is indicated as an aid in the assessment of patients for whom HERCEPTIN(R)(Transtuzumab) treatment is being considered.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • This is the earliest decision in FDA's data under product code MVC (SYSTEM, TEST, HER-2/NEU, IHC).
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Agilent Technologies Singapore (International) Pte , Ltd.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.